DPP-4 Inhibitor and Serum BNP Level of Diabetic Patients With Congestive Heart Failure

Overview

We thought to investigate the influence of DPP-4 inhibitor on the serum BNP level of diabetic patients with congestive heart failure. This study consists of two protocols. In the first protocol, diabetic patients with high level of serum BNP (100-2000 pg/ml) receiving outpatient treatment with any type of DPP-4 inhibitor at our institution will be enrolled. After baseline data collection, DPP-4 inhibitor will be suspended for one month and serum BNP will be measured. The DPP-4 inhibitor will be resumed and after another month, serum BNP will be measured again. In the other protocol, diabetic patients who were hospitalized due to heart failure were enrolled. DPP-4 inhibitor will be started (if the patient is not taking a DPP-4 inhibitor) or suspended (if the patient is taking a DPP-4 inhibitor) after stabilization of heart failure, and serum BNP will be measured before and after the drug administration or suspension.

Full Title of Study: “Investigation of the Impact of Dipeptidyl Peptidase-4 (DPP-4) Inhibition on Serum B-type Natriuretic Peptide (BNP) Level of Diabetic Patients With Congestive Heart Failure.”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Non-Randomized
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: March 2016

Interventions

  • Drug: Suspending DPP-4 inhibitor, in outpatient service
    • After baseline data collection, DPP-4 inhibitor (sitagliptin, vildagliptin, alogliptin, linagliptin, teneligliptin, anagliptin or saxagliptin) will be suspended for one month and serum BNP will be measured. The DPP-4 inhibitor will be resumed and after another month, serum BNP will be measured again.
  • Drug: Starting DPP-4 inhibitor after treatment of heart failure
    • After hospitalization, medication for diabetes will be suspended. During the treatment for heart failure, drugs other than DPP-4 inhibitor will be resumed when required. After the stabilization of heart failure, DPP-4 inhibitor will be resumed (or administered if it was not prescribed before hospitalization) and serum BNP before and after the initiation of DPP-4 inhibitor will be measured.
  • Drug: Suspending DPP-4 inhibitor after treatment of heart failure
    • After hospitalization, medication for diabetes may be suspended or continued. During the treatment for heart failure, drugs including DPP-4 inhibitor will be resumed when required. After the stabilization of heart failure, DPP-4 inhibitor will be suspended and serum BNP before and after the suspension of DPP-4 inhibitor will be measured.

Arms, Groups and Cohorts

  • Experimental: Outpatient arm
    • After baseline data collection, DPP-4 inhibitor will be suspended for one month and serum BNP will be measured. The DPP-4 inhibitor will be resumed and after another month, serum BNP will be measured again.
  • Experimental: Hospitalization arm 1
    • After hospitalization, medication for diabetes will be suspended. During the treatment for heart failure, drugs other than DPP-4 inhibitor will be resumed when required. After the stabilization of heart failure, DPP-4 inhibitor will be resumed (or administered if it was not prescribed before hospitalization) and serum BNP before and after the initiation of DPP-4 inhibitor will be measured.
  • Experimental: Hospitalization arm 2
    • After hospitalization, medication for diabetes may be suspended or continued. During the treatment for heart failure, drugs including DPP-4 inhibitor will be resumed when required. After the stabilization of heart failure, DPP-4 inhibitor will be suspended and serum BNP before and after the suspension of DPP-4 inhibitor will be measured.

Clinical Trial Outcome Measures

Primary Measures

  • Serum BNP level with and without DPP-4 inhibitor use.
    • Time Frame: 3 days to 2 months
    • In the outpatient arm, changes in serum BNP level measured 1 month after suspension of DPP-4 inhibitor, and 1month after resumption of the DPP-4 inhibitor will be analyzed. In the hospitalization arm, serum BNP before and 2-3 days after the initiation of DPP-4 inhibitor will be measured and compared.

Secondary Measures

  • All cause mortality
    • Time Frame: 2 months
    • Any deaths during the study period. (only for the outpatient arm)
  • Cardiovascular death
    • Time Frame: 2 months
    • Any cardiovascular deaths during the study period. (only for the outpatient arm)
  • Heart failure hospitalization
    • Time Frame: 2 months
    • Any hospitalization due to worsening of heart failure during suspension of or within 1month after resumption of taking a DPP-4 inhibitor. (only for the outpatient arm)
  • Worsening heart failure
    • Time Frame: 3 days
    • Worsening of heart failure after the initiation of DPP-4 inhibitor. (only for the hospitalization arm)
  • Echocardiographic measures (Changes in echocardiographic measures during the study period.)
    • Time Frame: 3 days to 2 months
  • Other neurohormonal factors (Changes in plasma renin, aldosterone, serum stromal cell-derived factor 1 alpha, serum active glucagon-like peptide-1, serum active glucose-dependent insulinotropic polypeptid)
    • Time Frame: 3 days to 2 months
    • Changes in plasma renin, aldosterone, serum stromal cell-derived factor 1 alpha, serum active glucagon-like peptide-1, serum active glucose-dependent insulinotropic polypeptide during the study period.

Participating in This Clinical Trial

Outpatient arm Inclusion Criteria:

  • Type 2 diabetes patient with congestive heart failure under treatment with DPP-4 inhibitor (sitagliptin, vildagliptin, alogliptin, linagliptin, teneligliptin, anagliptin or saxagliptin) . – High serum BNP (100-2000pg/ml). – Patients who have given informed consent to participation in the study. Exclusion Criteria:

  • HbA1c over 9.0%. – Patients who changed medication within 1 months before inclusion. – Judged as ineligible by clinical investigators. Hospitalization arm Inclusion Criteria:

  • Type 2 diabetes patient who were hospitalized for congestive heart failure. – Patients who have given informed consent to participation in the study. Exclusion Criteria:

  • Patients on insulin therapy. – Judged as ineligible by clinical investigators.

Gender Eligibility: All

Minimum Age: 20 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Mitsui Memorial Hospital
  • Collaborator
    • Mitsukoshi Health and Welfare Foundation
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Akihiro Isogawa, M.D., Principal Investigator, Mitusui Memorial Hospital, Division of diabetes

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.